A renal and hepatic toxicity analysis of remdesivir formulations: Does what is on the inside really count?

Antimicrob Agents Chemother. 2021 Jul 26:AAC0104521. doi: 10.1128/AAC.01045-21. Online ahead of print.ABSTRACTIt has been postulated that the injectable solution formulation of remdesivir could be more nephrotoxic than the lyophilized powder since it contains twice as much sulfobutylether-β-cyclodextrin (SBECD). Therefore, we evaluated 1000 hospitalized patients with SARS-CoV-2 who received remdesivir lyophilized powder or solution. A logistic regression model accounting for baseline confounders identified that neither the use of the injectable solution (OR = 1.05; 95% CI = 0.49-2.29; P=0.901) nor a Creatinine Clearance < 30ml/min at the time of remdesivir initiation (OR = 1.39; 95% CI = 0.51-3.5; P=0.499) were significantly associated with acute kidney injury. Regarding hepatoxicity, there was no significant difference in early discontinuation of remdesivir due to abnormal Liver Function Tests between patients who received the lyophilized powder versus solution (0.9% vs 2.3%, P= 0.09).PMID:34310212 | DOI:10.1128/AAC.01045-21
Source: Antimicrobial Agents and Chemotherapy - Category: Microbiology Authors: Source Type: research